Public Health Emergency - Leading a Nation Prepared
Over 50 BARDA-supported medical countermeasures have been FDA licensed, cleared or approved. By cultivating unique partnerships with industry, BARDA has built a portfolio of medical countermeasures to strengthen health security.
OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. The test will be used to detect the Ebola virus antigens in human blood from certain living individuals and from the oral fluids from certain recently deceased individuals suspected to have died from Ebola.
BARDA will support development of organ-on-a-chip technology to find out if the technology accurately models the effects and injuries that chlorine causes in human lungs. An organ-on-a-chip functions outside the body and contains the cells and molecules, fluids, and airflow that allow the model organ to simulate the function of a human organ.
After working with NIH/NIAID on early development of vaccines against the Marburg virus & the Sudan ebolavirus, Sabin Vaccine Institute will transition both vaccines to BARDA’s advanced development portfolio. The new public-private partnership aims to develop two vaccines simultaneously which could speed development and be more cost effective.
Treatments for smallpox remain a long-standing U.S. biodefense goal and a commitment to the international community. To that end, BARDA will collaborate with BioFactura to develop a novel therapeutic treatment for smallpox infections. Vaccines require at least two weeks to boost the immune system enough to prevent infection. Having therapeutic options available would be essential to saving lives.
